NCT06997458Enrolling by invitation
Liquid BiOpsy, Lung and Colon Cancer in AndaluciA
Clinical Implementation of Liquid Biopsy in Cancer Through Next Generation Sequencing (NGS) Panels in the Andalusian Public Health System
Source: ClinicalTrials.gov · Last updated 30 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The objective of the LOLA Project is to analyse the impact of adopting xF liquid biopsy panel, in the real world of the Andalusian Health Public System in terms of impact on clinical practice and cost through the assessment of clinical impact, duration of turnaround time (TAT) of xF test vs standard of care and the analysis of resource utilisation.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 25 Apr 2025
- Start date
- 1 Aug 2024
- Primary completion date
- 30 Jul 2025
- Lead sponsor
- Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
- Diseases
- Lung cancer, Colorectal cancer
- NCT number
- NCT06997458
What you commit to
- Study type: Observational
- Planned participants: 500
- From 1 Aug 2024 to the primary completion date, 30 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- General: History of any other cancer within the previous 5 years, except non-melanoma skin cancer
Other illness
- General: Absence of Informed consent. \> Pregnant or nursing women. \> Small cell lung cancer.
Who the study is looking for
- General criteria:
- More than 18 years old
- Both genders
- Ability to provide written informed consent
- Specific criteria:
- NSCLC
- Patients diagnosed with the 8th Edition of the Tumor, Node, Metastasis (TNM) staging system for Lung Cancer approved by International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
- Histologically confirmed NSCLC (adenocarcinoma)
- Performance status of 0-2 (ECOG PS) ○ Estimated life expectancy ≥3 months
- Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
- Smokers or Non-Smokers
- CRC
- Patients diagnosed with the Tumor, Node, Metastasis (TNM) staging system for Colorectal Cancer approved by the American Joint Committee on Cancer (AJCC): IV (Any T, Any N, M1a-c)
- Histologically confirmed CRC (adenocarcinoma)
- Performance status of 0-2 (ECOG PS)
- Estimated life expectancy ≥3 months
- Treatment naïve patients (chemotherapy, immunotherapy, targeted therapy, radiotherapy).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO) Coordinator of this site? Confirm its status | Granada | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.